AstraZeneca Pharma India receives notice of termination from AstraZeneca UK

24 Aug 2016 Evaluate

AstraZeneca Pharma India has received a notice of termination from AstraZeneca UK, conveying its decision for termination of distribution arrangements for Meronem in India. This is as a result of a global agreement by AstraZeneca PLC to sell the development and commercialization rights to Pfizer Inc, of its late-stage small molecule antibiotics business.

Meronem is a carbapenem anti-bacterial used for the treatment of serious infections in hospitalized patients. The transaction reinforces AstraZeneca’s focus on developing transformational medicines in its three main therapy areas viz., Cardiovascular and Metabolic Diseases, Respiratory and Oncology, while realizing value from the strong portfolio of established and late-stage antibiotics programs through Pfizer’s dedicated development and commercialization capabilities.

The current distribution arrangements for Meronem in India will terminate in six months from August 24, 2016.

AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.


Astrazeneca Pharma I Share Price

8908.70 -254.05 (-2.77%)
26-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1269.05
Cipla 1505.05
Zydus Lifesciences 911.50
Lupin 2112.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×